Literature DB >> 28100551

Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis.

Jeffrey J Swigris1, Dirk Esser2, Hilary Wilson3, Craig S Conoscenti4, Hendrik Schmidt5, Wibke Stansen5, Nancy Kline Leidy3, Kevin K Brown6.   

Abstract

The St George's Respiratory Questionnaire (SGRQ) has been used to measure health-related quality of life (HRQoL) in patients with idiopathic pulmonary fibrosis (IPF).This analysis evaluated the psychometric properties of the SGRQ using data from 428 patients with IPF who participated in a 12-month, randomised, placebo-controlled phase II trial of nintedanib.Internal consistency (Cronbach's α) was 0.91 for SGRQ total and >0.70 for domain scores. Test-retest reliability (intraclass correlation coefficients) was 0.77, 0.77, 0.69 and 0.66 for SGRQ total, activity, impact and symptoms scores, respectively. Construct validity of SGRQ total and domain scores was supported by weak to moderate cross-sectional correlations with the Medical Research Council dyspnoea scale (0.32-0.55), 6-min walk test distance (-0.25- -0.34), percentage predicted forced vital capacity (-0.11- -0.15) and measures of gas exchange (-0.26-0.03). There was some evidence that the SGRQ total score was sensitive to detecting change.The reliability, construct validity and responsiveness of the SGRQ in patients with IPF suggest that this is an acceptable measure of HRQoL in patients with IPF.
Copyright ©ERS 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28100551     DOI: 10.1183/13993003.01788-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  14 in total

1.  Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.

Authors:  Wim A Wuyts; Caroline Dahlqvist; Hans Slabbynck; Marc Schlesser; Natacha Gusbin; Christophe Compere; Sofie Maddens; Klaus-Uwe Kirchgaessler; Karen Bartley; Benjamin Bondue
Journal:  BMJ Open Respir Res       Date:  2018-11-21

2.  Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis.

Authors:  Thomas Skovhus Prior; Nils Hoyer; Ole Hilberg; Saher Burhan Shaker; Jesper Rømhild Davidsen; Elisabeth Bendstrup
Journal:  Respir Res       Date:  2020-04-21

3.  Improvement in Subjective Symptoms and Tolerability in Response to Nintedanib Treatment in Elderly Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Takayuki Takeda; Yusuke Kunimatsu; Nozomi Tani; Izumi Hashimoto; Yuri Kurono; Kazuki Hirose
Journal:  J Clin Med       Date:  2020-03-11       Impact factor: 4.241

4.  Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.

Authors:  Michael Kreuter; Wim A Wuyts; Marlies Wijsenbeek; Sabrina Bajwah; Toby M Maher; Susanne Stowasser; Natalia Male; Wibke Stansen; Nils Schoof; Leticia Orsatti; Jeffrey Swigris
Journal:  Respir Res       Date:  2020-01-30

5.  Comparison of Residual Pulmonary Abnormalities 3 Months After Discharge in Patients Who Recovered From COVID-19 of Different Severity.

Authors:  Mei Zhou; Juanjuan Xu; Tingting Liao; Zhengrong Yin; Fan Yang; Kai Wang; Zhen Wang; Dan Yang; Sufei Wang; Yi Peng; Shuyi Peng; Feihong Wu; Leqing Chen; Yang Jin
Journal:  Front Med (Lausanne)       Date:  2021-06-25

6.  Reliability and validity of the Glittre-ADL test to assess the functional status of patients with interstitial lung disease.

Authors:  Hellen Fontão Alexandre; Katerine Cristhine Cani; Juliana Araújo; Anamaria Fleig Mayer
Journal:  Chron Respir Dis       Date:  2021 Jan-Dec       Impact factor: 2.444

7.  Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials.

Authors:  Jeffrey J Swigris; Hilary Wilson; Dirk Esser; Craig S Conoscenti; Wibke Stansen; Nancy Kline Leidy; Kevin K Brown
Journal:  BMJ Open Respir Res       Date:  2018-05-18

Review 8.  Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives.

Authors:  Bridget A Graney; Joyce S Lee
Journal:  Patient Relat Outcome Meas       Date:  2018-09-21

9.  Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry.

Authors:  Amy Hajari Case; Anne S Hellkamp; Megan L Neely; Shaun Bender; Daniel F Dilling; Mridu Gulati; David L Hotchkin; Tristan J Huie; Lisa Lancaster; Laurie D Snyder; Craig S Conoscenti; Scott M Palmer
Journal:  Ann Am Thorac Soc       Date:  2020-06

Review 10.  Minimal clinically important difference in idiopathic pulmonary fibrosis.

Authors:  Mohleen Kang; Lucian Marts; Jordan A Kempker; Srihari Veeraraghavan
Journal:  Breathe (Sheff)       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.